Similar articles

• Surgical treatment of neuroblastoma with micrometastasis.

  Kuroda T, Saeki M, Nakano M, Mizutani S, Endo M, Akiyama H. Kuroda T, et al. J Pediatr Surg. 2000 Nov;35(11):1638-42. doi: 10.1053/jpsu.2000.18341. J Pediatr Surg. 2000. PMID: 11083442
• Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.

  Horibe K, Fukuda M, Miyajima Y, Matsumoto K, Kondo M, Inaba J, Miyashita Y. Horibe K, et al. Med Pediatr Oncol. 2001 Jan;36(1):203-4. doi: 10.1002/1096-911X(20010101)36:1<203::AID-MPO1049>3.0.CO;2-T. Med Pediatr Oncol. 2001. PMID: 11464885
• Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.

  Krams M, Hero B, Berthold F, Parwaresch R, Harms D, Rudolph P. Krams M, et al. Cancer. 2002 Feb 1;94(3):854-61. Cancer. 2002. PMID: 11857322
• [Prognosis of neuroblastoma in childhood. Methods of assessment and clinical use].

  Pérel Y, Valteau-Couanet D, Michon J, Lavrand F, Coze C, Bergeron C, Notz A, Plantaz D, Chastagner P, Bernard F, Thomas C, Rubie H. Pérel Y, et al. Arch Pediatr. 2004 Jul;11(7):834-42. doi: 10.1016/j.arcped.2004.02.022. Arch Pediatr. 2004. PMID: 15234382 Review. French.
• Screening for neuroblastoma: progress and pitfalls.

  Ross JA, Davies SM. Ross JA, et al. Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):189-94. Cancer Epidemiol Biomarkers Prev. 1999. PMID: 10067819 Review. No abstract available.